Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.89 USD
Change Today +0.55 / 5.89%
Volume 5.0M
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

achillion pharmaceuticals (ACHN) Snapshot

Open
$9.29
Previous Close
$9.34
Day High
$9.91
Day Low
$9.27
52 Week High
12/22/14 - $16.87
52 Week Low
06/2/14 - $2.65
Market Cap
1.2B
Average Volume 10 Days
6.8M
EPS TTM
$-0.70
Shares Outstanding
117.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACHILLION PHARMACEUTICALS (ACHN)

achillion pharmaceuticals (ACHN) Related Businessweek News

No Related Businessweek News Found

achillion pharmaceuticals (ACHN) Details

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections. The company’s drug candidates for treating chronic HCV infection comprise ACH-3102, a NS5A inhibitor, which completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor that is in Phase I clinical development; and Sovaprevir, a NS3 protease inhibitor, which completed Phase II clinical trial. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally; and license and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize the company’s hepatitis C virus assets. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

67 Employees
Last Reported Date: 03/5/15
Founded in 1998

achillion pharmaceuticals (ACHN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $484.1K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $347.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $457.6K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $335.4K
Compensation as of Fiscal Year 2014.

achillion pharmaceuticals (ACHN) Key Developments

Achillion Pharmaceuticals Inc. Enters into Worldwide License and Collaboration Arrangement with Janssen Pharmaceuticals

Achillion Pharmaceuticals Inc. (ACHN) has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals Inc., to develop and commercialize one or more of Achillion's lead hepatitis C virus assets which include ACH-3102, ACH-3422, and Sovaprevir. The collaboration focuses on the development of a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of hepatitis C virus, or HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in phase 2 clinical studies in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration. Achillion is eligible to receive about $1.1 billion in potential development, regulatory and sales milestone payments under the collaboration. Additionally, Johnson & Johnson Innovation - JJDC, Inc. will invest $225 million in Achillion and, in return, receive about 18.4 million newly issued, unregistered shares of Achillion at a price of $12.25 per share. Derma Sciences Inc. (DSCI) is aiming to complete enrollment in its phase III program with Aclerastide in subjects with diabetic foot ulcers by the end of June 2016.

Achillion Pharmaceuticals Enters into Worldwide License and Collaboration Arrangement with Janssen Pharmaceuticals, Inc

Achillion Pharmaceuticals entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, Inc. to develop and commercialize one or more of Achillion's lead hepatitis C virus (HCV) assets which include ACH-3102, ACH-3422, and sovaprevir. Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets. A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration.

Achillion Pharmaceuticals, Inc. - Special Call

To discuss worldwide license and collaboration arrangement with Janssen Pharmaceuticals, Inc. to develop and commercialize one or more of the company's lead hepatitis C virus (HCV) assets which include ACH-3102, ACH-3422, and sovaprevir

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACHN:US $9.89 USD +0.55

ACHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,373 GBp -119.50
Bavarian Nordic A/S kr336.50 DKK +3.00
Bayer AG €129.91 EUR -3.61
Chimerix Inc $41.85 USD +0.24
Emergent Biosolutions Inc $31.86 USD +0.11
View Industry Companies
 

Industry Analysis

ACHN

Industry Average

Valuation ACHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHILLION PHARMACEUTICALS, please visit www.achillion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.